A citation-based method for searching scientific literature

Asger Lund, Tina Vilsbøll, Jonatan I Bagger, Jens J Holst, Filip K Knop. Am J Physiol Endocrinol Metab 2011
Times Cited: 102







List of co-cited articles
1106 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity





Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans.
Mikkel Christensen, Louise Vedtofte, Jens J Holst, Tina Vilsbøll, Filip K Knop. Diabetes 2011
177
24

Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes.
Chee W Chia, Olga D Carlson, Wook Kim, Yu-Kyong Shin, Cornelia P Charles, Hee Seung Kim, Denise L Melvin, Josephine M Egan. Diabetes 2009
106
23

Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia.
J J Meier, B Gallwitz, N Siepmann, J J Holst, C F Deacon, W E Schmidt, M A Nauck. Diabetologia 2003
215
22

Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
22

Impaired regulation of the incretin effect in patients with type 2 diabetes.
Jonatan I Bagger, Filip K Knop, Asger Lund, Henrik Vestergaard, Jens J Holst, Tina Vilsbøll. J Clin Endocrinol Metab 2011
140
20

GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes.
Nikolaos Mentis, Irfan Vardarli, Lars D Köthe, Jens J Holst, Carolyn F Deacon, Michael Theodorakis, Juris J Meier, Michael A Nauck. Diabetes 2011
95
20

Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses.
M A Nauck, E Homberger, E G Siegel, R C Allen, R P Eaton, R Ebert, W Creutzfeldt. J Clin Endocrinol Metab 1986
568
18

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes.
M Nauck, F Stöckmann, R Ebert, W Creutzfeldt. Diabetologia 1986
873
18



Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus.
P Shah, A Vella, A Basu, R Basu, W F Schwenk, R A Rizza. J Clin Endocrinol Metab 2000
298
14

Glucagon-like peptide-1 7-36: a physiological incretin in man.
B Kreymann, G Williams, M A Ghatei, S R Bloom. Lancet 1987
14

Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains.
Jesper Gromada, Isobel Franklin, Claes B Wollheim. Endocr Rev 2007
398
14

The physiology of glucagon-like peptide 1.
Jens Juul Holst. Physiol Rev 2007
14


The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action.
Kristine J Hare, Tina Vilsbøll, Meena Asmar, Carolyn F Deacon, Filip K Knop, Jens J Holst. Diabetes 2010
168
13

Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans.
Juris J Meier, Michael A Nauck, Andrea Pott, Kai Heinze, Oliver Goetze, Kerem Bulut, Wolfgang E Schmidt, Baptist Gallwitz, Jens J Holst. Gastroenterology 2006
171
13

Inhibition of gastric inhibitory polypeptide signaling prevents obesity.
Kazumasa Miyawaki, Yuichiro Yamada, Nobuhiro Ban, Yu Ihara, Katsushi Tsukiyama, Heying Zhou, Shimpei Fujimoto, Akira Oku, Kinsuke Tsuda, Shinya Toyokuni,[...]. Nat Med 2002
610
13

Pharmacology, physiology, and mechanisms of incretin hormone action.
Jonathan E Campbell, Daniel J Drucker. Cell Metab 2013
745
13

Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes.
Mikkel B Christensen, Salvatore Calanna, Jens J Holst, Tina Vilsbøll, Filip K Knop. J Clin Endocrinol Metab 2014
49
26

Evidence of Extrapancreatic Glucagon Secretion in Man.
Asger Lund, Jonatan I Bagger, Nicolai J Wewer Albrechtsen, Mikkel Christensen, Magnus Grøndahl, Bolette Hartmann, Elisabeth R Mathiesen, Carsten P Hansen, Jan H Storkholm, Gerrit van Hall,[...]. Diabetes 2016
94
13

Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity.
Filip K Knop, K Aaboe, T Vilsbøll, A Vølund, J J Holst, T Krarup, S Madsbad. Diabetes Obes Metab 2012
109
12

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Juan Pablo Frias, Michael A Nauck, Joanna Van, Mark E Kutner, Xuewei Cui, Charles Benson, Shweta Urva, Ruth E Gimeno, Zvonko Milicevic, Deborah Robins,[...]. Lancet 2018
237
12

Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes.
Kristine J Hare, Tina Vilsbøll, Jens J Holst, Filip K Knop. Am J Physiol Endocrinol Metab 2010
49
22

Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?
Filip K Knop, Tina Vilsbøll, Patricia V Højberg, Steen Larsen, Sten Madsbad, Aage Vølund, Jens J Holst, Thure Krarup. Diabetes 2007
217
11


Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus.
Kristine J Hare, Filip K Knop, Meena Asmar, Sten Madsbad, Carolyn F Deacon, Jens J Holst, Tina Vilsbøll. J Clin Endocrinol Metab 2009
70
15



Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies.
Salvatore Calanna, Mikkel Christensen, Jens J Holst, Blandine Laferrère, Lise L Gluud, Tina Vilsbøll, Filip K Knop. Diabetes Care 2013
86
12

Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
Brian Finan, Tao Ma, Nickki Ottaway, Timo D Müller, Kirk M Habegger, Kristy M Heppner, Henriette Kirchner, Jenna Holland, Jazzminn Hembree, Christine Raver,[...]. Sci Transl Med 2013
284
11

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.
Brian Finan, Bin Yang, Nickki Ottaway, David L Smiley, Tao Ma, Christoffer Clemmensen, Joe Chabenne, Lianshan Zhang, Kirk M Habegger, Katrin Fischer,[...]. Nat Med 2015
304
10

Reappraisal of GIP Pharmacology for Metabolic Diseases.
Brian Finan, Timo D Müller, Christoffer Clemmensen, Diego Perez-Tilve, Richard D DiMarchi, Matthias H Tschöp. Trends Mol Med 2016
80
12

Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies.
Christof M Kazda, Ying Ding, Ronan P Kelly, Parag Garhyan, Chunxue Shi, Chay Ngee Lim, Haoda Fu, David E Watson, Andrew J Lewin, William H Landschulz,[...]. Diabetes Care 2016
106
10

Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes.
J J Meier, K Hücking, J J Holst, C F Deacon, W H Schmiegel, M A Nauck. Diabetes 2001
159
9


Stimulation of insulin secretion by gastric inhibitory polypeptide in man.
J Dupre, S A Ross, D Watson, J C Brown. J Clin Endocrinol Metab 1973
711
9

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
A Flint, A Raben, A Astrup, J J Holst. J Clin Invest 1998
926
9

Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.
D R Matthews, J P Hosker, A S Rudenski, B A Naylor, D F Treacher, R C Turner. Diabetologia 1985
9

Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes.
Jens J Holst, Filip K Knop, Tina Vilsbøll, Thure Krarup, Sten Madsbad. Diabetes Care 2011
172
9

Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals.
Lærke S Gasbjerg, Mads M Helsted, Bolette Hartmann, Mette H Jensen, Maria B N Gabe, Alexander H Sparre-Ulrich, Simon Veedfald, Signe Stensen, Amalie R Lanng, Natasha C Bergmann,[...]. Diabetes 2019
55
16


GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis.
Yang Z De Marinis, Albert Salehi, Caroline E Ward, Quan Zhang, Fernando Abdulkader, Martin Bengtsson, Orit Braha, Matthias Braun, Reshma Ramracheya, Stefan Amisten,[...]. Cell Metab 2010
175
8

Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.
M B Toft-Nielsen, M B Damholt, S Madsbad, L M Hilsted, T E Hughes, B K Michelsen, J J Holst. J Clin Endocrinol Metab 2001
617
8

Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.
Alessandro Pocai, Paul E Carrington, Jennifer R Adams, Michael Wright, George Eiermann, Lan Zhu, Xiaobing Du, Aleksandr Petrov, Michael E Lassman, Guoqiang Jiang,[...]. Diabetes 2009
260
8




Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.